Fighting Cancer with Nanoparticle Medicines: The Nanoscale Matters!
Event details
| Date | 30.04.2012 |
| Hour | 11:15 › 12:15 |
| Speaker | Prof. Mark E. Davis, Caltech, Pasadena (USA) |
| Location | |
| Category | Conferences - Seminars |
Abstract
Papyrus writings from 1600-1500 BC describe cancer and attempts at its treatment. Today, centuries later, cancer remains a devastating disease. Given the long history of difficulties in developing cancer therapies, why is there excitement about nanoparticle medicine (nanomedicines) for fighting cancer? In this lecture, I will present the current understandings of why these engineered, nanosized medicines (that are highly multifunctional chemical systems) have the potential to provide “game changing” ways to treat cancer. The nanoscale matters. I will illustrate this point by demonstrating how physical insights at the nanoscale allow for the development of nanoparticles that can function as intended in animals and humans. The data from humans will be used to show how we have translated two independent nanoparticle cancer therapeutics from laboratory curiosities to experimental therapeutics in human clinical trials.
Papyrus writings from 1600-1500 BC describe cancer and attempts at its treatment. Today, centuries later, cancer remains a devastating disease. Given the long history of difficulties in developing cancer therapies, why is there excitement about nanoparticle medicine (nanomedicines) for fighting cancer? In this lecture, I will present the current understandings of why these engineered, nanosized medicines (that are highly multifunctional chemical systems) have the potential to provide “game changing” ways to treat cancer. The nanoscale matters. I will illustrate this point by demonstrating how physical insights at the nanoscale allow for the development of nanoparticles that can function as intended in animals and humans. The data from humans will be used to show how we have translated two independent nanoparticle cancer therapeutics from laboratory curiosities to experimental therapeutics in human clinical trials.
Links
Practical information
- Informed public
- Free
- This event is internal
Organizer
- joint seminar of the Institute of Bioengineering (IBI) and the ISREC, hosted by Profs. Melody Swartz and Jeffrey Hubbell
Contact
- D. Reinhard, IBI ([email protected] / 3 16 43)